in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new role for former Genzyme CEO and a leadership change at Astellas Europe.
Henri Termeer has joined the board of directors at AVEO Pharmaceuticals. Termeer was CEO, chairman and president of Genzyme but has stepped down following completion of the takeover by Sanofi-aventis.
Astellas Pharma Europe has promoted Ken Jones to the positions of president and CEO, succeeding Masao Yoshida. Jones has worked as chief operating officer of the company since July 2007.
Peter Hansbury has joined AMRI as vice president (VP) of aseptic services. The position gives Hansbury leadership of the aseptic fill and finish facility in Burlington, Massachusetts. In his 30 years working in sterile products Hansbury has held positions Ben Venue and LyphoMed.
Ectycell, a subsidiary of Cellectis, has strengthened management with three hires. Edward Balbirnie has been named chief operating officer. Balbirnie has bioproduction and quality assurance experience from working at LFB Biotechnologies and Elan.
Also, Stephan Reynier, formerly of Gilead Sciences, joins as head of programs and Wu Ma has been named head of the induced pluripotent stem (iPS) cell platform. Ma previously worked at iPierian.
Aileron Therapeutics has appointed Anthony Manning, formerly of Biogen Idec, as SVP of research and preclinical development. Also, Yong Chang has left MedImmune to join Aileron as head of biology.
Richard Bergström has succeeded Brian Ager as director general of the European Federation of the Pharmaceutical Industries and Associations (EFPIA). Bergström was director general of LIF, a pharmaceutical industry association, and has also worked at Novartis and Roche.